OPKO Health Files 8-K/A Amendment
Ticker: OPK · Form: 8-K/A · Filed: Mar 28, 2024 · CIK: 944809
| Field | Detail |
|---|---|
| Company | Opko Health, INC. (OPK) |
| Form Type | 8-K/A |
| Filed Date | Mar 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, disclosure
Related Tickers: OPK
TL;DR
OPKO Health filed an amendment to an earlier report on 3/28/24. No new material info.
AI Summary
OPKO Health, Inc. filed an 8-K/A on March 28, 2024, to amend a previous filing. The amendment pertains to Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain new material information beyond what was previously disclosed.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information by OPKO Health, Inc.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing and does not introduce new material events or financial information.
Key Players & Entities
- OPKO Health, Inc. (company) — Registrant
- March 28, 2024 (date) — Date of earliest event reported
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previously filed report, specifically concerning Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 28, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 4400 Biscayne Blvd., Miami, Florida 33137.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 75-2402409.
What is the SIC code for OPKO Health, Inc.?
The Standard Industrial Classification code for OPKO Health, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-03-28 11:06:39
Key Financial Figures
- $0.01 — ch registered Common Stock , par value $0.01 per share OPK NASDAQ Global Select M
Filing Documents
- opk20240328_8ka.htm (8-K/A) — 27KB
- ex_646825.htm (EX-2.1) — 551KB
- ex_646807.htm (EX-99.1) — 13KB
- page1c.jpg (GRAPHIC) — 53KB
- page2d.jpg (GRAPHIC) — 251KB
- page3c.jpg (GRAPHIC) — 171KB
- page4c.jpg (GRAPHIC) — 196KB
- page5c.jpg (GRAPHIC) — 171KB
- page6c.jpg (GRAPHIC) — 142KB
- page7c.jpg (GRAPHIC) — 192KB
- page8c.jpg (GRAPHIC) — 170KB
- page10c.jpg (GRAPHIC) — 157KB
- page11c.jpg (GRAPHIC) — 177KB
- page12c.jpg (GRAPHIC) — 137KB
- page13c.jpg (GRAPHIC) — 36KB
- page14c.jpg (GRAPHIC) — 122KB
- page15c.jpg (GRAPHIC) — 212KB
- page16c.jpg (GRAPHIC) — 139KB
- page17c.jpg (GRAPHIC) — 191KB
- page18c.jpg (GRAPHIC) — 200KB
- page19c.jpg (GRAPHIC) — 41KB
- page20c.jpg (GRAPHIC) — 213KB
- page21c.jpg (GRAPHIC) — 168KB
- page22c.jpg (GRAPHIC) — 40KB
- page23c.jpg (GRAPHIC) — 197KB
- page24c.jpg (GRAPHIC) — 28KB
- 0001437749-24-009735.txt ( ) — 5517KB
- opk-20240328.xsd (EX-101.SCH) — 3KB
- opk-20240328_def.xml (EX-101.DEF) — 12KB
- opk-20240328_lab.xml (EX-101.LAB) — 15KB
- opk-20240328_pre.xml (EX-101.PRE) — 12KB
- opk20240328_8ka_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 2.1* A sset Purchase Agreement, dated as of March 27, 2024 by and among BioReference Health, LLC, OPKO Health, Inc. and Laboratory Corporation of America Holdings 99.1 Investor Presentation, dated March 27, 2024 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document * Pursuant to Item 601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and such information is not otherwise disclosed in such exhibit. The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S. Securities and Exchange Commission or its staff upon request.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPKO Health, Inc. By: /s/ Steven D. Rubin Date: March 28, 2024 Name: Steven D. Rubin Title: Executive Vice President-Administration